Valuation conundrum of healthcare-related stocks in US and M’sia


THE United States, which is the epicentre of the Covid-19 pandemic, is the base for some of the world’s largest healthcare companies. These companies are in the race to find a vaccine for the virus and have from time to time disclosed the progress of finding a wonder drug to prevent the spread of the virus.

However, the valuations of the more established pharmaceutical companies have remained sober even though the companies are in the forefront of the search to find a vaccine.

The Star 6.6 DEAL: 35% OFF Digital Access

Monthly Plan

RM 13.90/month

RM 9.04/month

Billed as RM 9.04 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Stocks slide on flare-up of hostilities
Bursa Malaysia sees slight rebound as downside risks intensify
Trade policy concerns temper US$ strength, lifting ringgit
Trading ideas: Chin Hin, Citaglobal, ES Sunlogy, Malton, MCE, Orkim, Pan Merchant, Perdana, Ramssol, RHB, Vantris, Willowglen, BCorp, Dnex, PPB, SRKK
First-quarter earnings exceed expectations
MISC bags second LCO2 carrier charter from Northern Lights
Matrix Concepts unveils scholarship programme
Panasonic Manufacturing�Malaysia appoints new MD
Willowglen wins RM47mil contracts in Singapore
CGC to roll out RM10bil BNM-CGC financing plan

Others Also Read